Meeting
2016 Gastrointestinal Cancers Symposium
Feasibility and impact on resectability of FOLFIRINOX in locally-advanced and borderline pancreatic cancer.
Authors
Fabienne Portales
Institut Régional du Cancer de Montpellier, Montpellier, France
Fabienne Portales , Benedicte Gagniard , Simon Thezenas , Emmanuelle Samalin , Eric Assenat , Mathias Alline , Pierre-Emmanuel Colombo , Philippe Rouanet , Sebastien Carrere , François Quenet , Olivier Riou , Carmen Llacer , Thibault Mazard , Marc Ychou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 318)
DOI
10.1200/jco.2016.34.4_suppl.318
Abstract #
318
Poster Bd #
F20
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Do we need postoperative chemotherapy after preoperative FOLFIRINOX in resected borderline or locally advanced pancreatic cancer? A retrospective analysis.
First Author: Roxane Mari
Poster
2015 Gastrointestinal Cancers Symposium
Intensity-modulated radiation therapy (IMRT) in patients with locally advanced pancreatic cancer (LAPC).
First Author: Carla Hajj
Poster
2021 ASCO Annual Meeting
Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.
First Author: Andrew Oar
Poster
2020 ASCO Virtual Scientific Program
Safety and efficacy of biweekly gemcitabine in combination with capecitabine (GemCap) in elderly and frail patients (pts) with resected pancreatic cancer (PC).
First Author: Nausheen Hakim